Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
Top Cited Papers
- 1 September 2010
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (9) , 3251-3257
- https://doi.org/10.1128/jcm.00536-10
Abstract
Clinical breakpoints have not been established for mold testing. Wild-type (WT) MIC distributions (organisms in a species/drug combination with no detectable acquired resistance mechanisms) were defined in order to establish epidemiologic cutoff values (ECVs) for five Aspergillus spp. and itraconazole, posaconazole, and voriconazole. Also, we have expanded prior ECV data for Aspergillus fumigatus. The number of available isolates varied according to the species/triazole combination as follows: 1,684 to 2,815 for A. fumigatus, 323 to 592 for A. flavus, 131 to 143 for A. nidulans, 366 to 520 for A. niger, 330 to 462 for A. terreus, and 45 to 84 for A. versicolor. CLSI broth microdilution MIC data gathered in five independent laboratories in Europe and the United States were aggregated for the analyses. ECVs expressed in microg/ml were as follows (percentages of isolates for which MICs were equal to or less than the ECV are in parentheses): A. fumigatus, itraconazole, 1 (98.8%); posaconazole, 0.5 (99.2%); voriconazole, 1 (97.7%); A. flavus, itraconazole, 1 (99.6%); posaconazole, 0.25 (95%); voriconazole, 1 (98.1%); A. nidulans, itraconazole, 1 (95%); posaconazole, 1 (97.7%); voriconazole, 2 (99.3%); A. niger, itraconazole, 2 (100%); posaconazole, 0.5 (96.9%); voriconazole, 2 (99.4%); A. terreus, itraconazole, 1 (100%); posaconazole, 0.5 (99.7%); voriconazole, 1 (99.1%); A. versicolor, itraconazole, 2 (100%); posaconazole, 1 (not applicable); voriconazole, 2 (97.5%). Although ECVs do not predict therapy outcome as clinical breakpoints do, they may aid in detection of azole resistance (non-WT MIC) due to cyp51A mutations, a resistance mechanism in some Aspergillus spp. These ECVs should be considered for inclusion in the future CLSI M38-A2 document revision.Keywords
This publication has 34 references indexed in Scilit:
- Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A GeneAntimicrobial Agents and Chemotherapy, 2010
- Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida sppJournal of Clinical Microbiology, 2010
- Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution MethodsJournal of Clinical Microbiology, 2009
- Species Identification and Antifungal Susceptibility Patterns of Species Belonging to Aspergillus Section NigriAntimicrobial Agents and Chemotherapy, 2009
- Frequency and Evolution of Azole Resistance inAspergillus fumigatusAssociated with Treatment Failure1Emerging Infectious Diseases, 2009
- In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance MechanismPLoS Medicine, 2008
- Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2008
- Setting and Revising Antibacterial Susceptibility BreakpointsClinical Microbiology Reviews, 2007
- A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A AlterationsAntimicrobial Agents and Chemotherapy, 2007